ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Meeting News

Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy

Haleigh Behrman
on: May 13, 2025In: Meeting News, Society News
Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy

Dr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC. Read more


Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC

Nathan Pettengill
on: May 13, 2025In: Meeting News, Society News
Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC

Research team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting. Read more

A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going

Haleigh Behrman
on: May 13, 2025In: Meeting News, Society News
A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going

Pioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC. Read more

A Real Tail in These Curves: A Look at Advances and Future Directions in SCLC

Haleigh Behrman
on: April 22, 2025In: Meeting News, Society News
A Real Tail in These Curves: A Look at Advances and Future Directions in SCLC

During a recent address at SCLC 2025, Dr. Charles Rudin discussed the progress being made in reducing the incidence of small cell lung cancer and in treating it. Read more

COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities

Nathan Pettengill
on: April 22, 2025In: Meeting News, Society News
COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities

Dr. Nicolas Girard recently presented data that shows prophylactic treatment with oral and topical antibiotics and ceramide-based moisturizer significantly reduced adverse skin events. Read more

Savolitinib Plus Osimertinib Offers Hope for Addressing Resistance, Progression

Nathan Pettengill
on: April 22, 2025In: Meeting News, Society News
Savolitinib Plus Osimertinib Offers Hope for Addressing Resistance, Progression

Dr. Myung-Ju Ahn said recent data from SAVANNAH show the combination produced a meaningful and durable response in patients whose cancer progressed after osimertinib. Read more

Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy

Haleigh Behrman
on: April 08, 2025In: Meeting News, Society News
Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy

Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress. Read more

Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award

Nathan Pettengill
on: April 08, 2025In: Meeting News, Names & News, Society News
Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award

During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology. Read more

Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?

Haleigh Behrman
on: March 25, 2025In: Evolving Standards of Care, Meeting News, Names & News
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?

During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more

With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma

Haleigh Behrman
on: March 25, 2025In: Evolving Standards of Care, Meeting News, Names & News
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma

Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more

1234›»

SEARCH ILCN

Archives

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy